FDA 483 - Seth M.Pollack, M.D. - June 27, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Fred Hutchinson Cancer Research Center in Seattle, WA, identified multiple significant deviations in the conduct of a clinical investigation. Key issues included enrolling ineligible subjects, failing to properly re-consent participants, not adhering to protocol-specified procedures, and deficiencies in IRB review and approval processes for informed consent documents and Investigator Brochures. These findings highlight critical lapses in clinical trial oversight and subject protection.
ID · 4d63d499-396f-418e-a39e-77334aea3480